I must be the only optiomist left. To me, i think clarification...

I must be the only optiomist left. To me, i think clarification around the trial design will give this a major boost. From what i can see, we cant be far off. We have the two lead investigators locked in, we have most the hospitals, we have podiums so the docs are talking about us as 30% better. Hopefully we get the small number of patients required and ongoing sales, then we are laughing. Not to mention a out of the blue viv approval.

I think the timing of nasdaq will be the cap raise for the trial. The term potential is just about recognising risk, not intent in my view. I wouldnt be surprised if they include it for regulatory reasons.